Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and toxicity of transarterial chemoembolization therapy using cisplatin and gelatin sponge in patients with liver metastases from uveal melanoma in an Asian population

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Although both immune-checkpoint inhibitors and targeted therapies such as MEK inhibitors have been evaluated in metastatic uveal melanoma, the efficacy of these therapies is modest to date. The purpose of this study was to evaluate the efficacy and toxicity of transarterial chemoembolization (TACE) therapy for liver metastasis from uveal melanoma in an Asian population.

Methods

We retrospectively assessed the clinical data of patients with liver metastases from uveal melanoma who received TACE therapy using cisplatin (70 mg/m2) and gelatin sponge between 1997 and 2008.

Results

We identified 29 eligible patients. The overall response rate was 21%. The median survival time was 23 months, and the 1-, 2-, and 5-year survival rates were 72.4, 39.4, and 0%, respectively. The favorable prognostic factors were partial response and stable disease, <25% of the tumor volume within the liver at baseline, and normal serum lactate dehydrogenase (LDH) and normal alkaline phosphatase at baseline. Among them, normal LDH at baseline was the only independent prognostic factor in multivariate analysis. The common adverse events (AEs) were liver enzyme elevation (100%), nausea (72.4%), abdominal pain (65.5%), vomiting (55.2%), post-embolization syndrome (34.5% of patients, 9.6% of TACE procedures), and pyrexia (24.1%). Grade ≥3 AEs consisted of aspartate aminotransferase elevation (34.5%), alanine aminotransferase elevation (51.7%), and serum creatinine elevation (3.4%).

Conclusion

TACE therapy has a certain degree of clinical efficacy with a tolerable toxicity and, therefore, can still be one of the treatment options. However, considering the lack of long-term efficacy of this therapy, further treatment strategies need to be developed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Zimmer L, Vaubel J, Mohr P et al (2015) Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PLoS One 10:e0118564

    Article  PubMed  PubMed Central  Google Scholar 

  2. Carvajal RD, Sosman JA, Quevedo JF et al (2014) Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA 311:2397–2405

    Article  PubMed  PubMed Central  Google Scholar 

  3. Hu DN, Yu GP, McCormick SA et al (2005) Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol 140:612–617

    Article  PubMed  Google Scholar 

  4. Fujisawa Y, Yamazaki N, Yamamoto A (2003) TAE therapy for metastatic melanoma to liver (in Japanese). MB Derma 77:38–43

    Google Scholar 

  5. Singh AD, Topham A (2003) Incidence of uveal melanoma in the United States: 1973–1997. Ophthalmology 110:956–961

    Article  PubMed  Google Scholar 

  6. Bedikian AY, Legha SS, Mavligit G et al (1995) Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 76:1665–1670

    Article  CAS  PubMed  Google Scholar 

  7. Khattak MA, Fisher R, Hughes P et al (2013) Ipilimumab activity in advanced uveal melanoma. Melanoma Res 23:79–81

    Article  CAS  PubMed  Google Scholar 

  8. Van Raamsdonk CD, Bezrookove V, Green G et al (2009) Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457:599–602

    Article  PubMed  Google Scholar 

  9. Van Raamsdonk CD, Griewank KG, Crosby MB et al (2010) Mutations in GNA11 in uveal melanoma. N Engl J Med 363:2191–2199

    Article  PubMed  PubMed Central  Google Scholar 

  10. Harbour JW, Onken MD, Roberson ED et al (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330:1410–1413

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Harbour JW, Roberson ED, Anbunathan H et al (2013) Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet 45:133–135

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Onken MD, Worley LA, Ehlers JP, Harbour JW (2004) Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 64:7205–7209

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Carrasco CH, Wallace S, Charnsangavej C et al (1986) Treatment of hepatic metastases in ocular melanoma. Embolization of the hepatic artery with polyvinyl sponge and cisplatin. JAMA 255:3152–3154

    Article  CAS  PubMed  Google Scholar 

  14. Mavligit GM, Charnsangavej C, Carrasco CH et al (1988) Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 260:974–976

    Article  CAS  PubMed  Google Scholar 

  15. Patel K, Sullivan K, Berd D et al (2005) Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res 15:297–304

    Article  PubMed  Google Scholar 

  16. Huppert PE, Fierlbeck G, Pereira P et al (2010) Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur J Radiol 74:e38–e44

    Article  CAS  PubMed  Google Scholar 

  17. Schuster R, Lindner M, Wacker F et al (2010) Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome. Melanoma Res 20:191–196

    CAS  PubMed  Google Scholar 

  18. Long GV, Grob JJ, Nathan P et al (2016) Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol 17:1743–1754

    Article  CAS  PubMed  Google Scholar 

  19. Diem S, Kasenda B, Spain L et al (2016) Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer 114:256–261

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Diem S, Kasenda B, Martin-Liberal J et al (2015) Prognostic score for patients with advanced melanoma treated with ipilimumab. Eur J Cancer 51:2785–2791

    Article  CAS  PubMed  Google Scholar 

  21. Gupta S, Bedikian AY, Ahrar J et al (2010) Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors. Am J Clin Oncol 33:474–480

    Article  PubMed  Google Scholar 

  22. Sato T, Eschelman DJ, Gonsalves CF et al (2008) Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 26:5436–5442

    Article  CAS  PubMed  Google Scholar 

  23. Dayani PN, Gould JE, Brown DB et al (2009) Hepatic metastasis from uveal melanoma: angiographic pattern predictive of survival after hepatic arterial chemoembolization. Arch Ophthalmol 127:628–632

    Article  PubMed  Google Scholar 

  24. Edelhauser G, Schicher N, Berzaczy D et al (2012) Fotemustine chemoembolization of hepatic metastases from uveal melanoma: a retrospective single-center analysis. Am J Roentgenol 199:1387–1392

    Article  Google Scholar 

  25. Valpione S, Aliberti C, Parrozzani R et al (2015) A retrospective analysis of 141 patients with liver metastases from uveal melanoma: a two-cohort study comparing transarterial chemoembolization with CPT-11 charged microbeads and historical treatments. Melanoma Res 25:164–168

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank Professor Hisatomi Arima from the Department of Preventive Medicine and Public Health, Faculty of Medicine, Fukuoka University for advice regarding statistical analyses. This work was partly supported by the National Cancer Center Research and Development Fund (26-A-4).

Author information

Authors and Affiliations

  1. Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Yoshitsugu Shibayama, Kenjiro Namikawa, Akira Takahashi, Arata Tsutsumida & Naoya Yamazaki

  2. Department of Dermatology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0133, Japan

    Yoshitsugu Shibayama, Juichiro Nakayama & Shinichi Imafuku

  3. Department of Diagnostic Radiology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Miyuki Sone, Shunsuke Sugawara & Yasuaki Arai

  4. Department of Ophthalmic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Yukiko Aihara & Shigenobu Suzuki

Authors
  1. Yoshitsugu Shibayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenjiro Namikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miyuki Sone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akira Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arata Tsutsumida
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shunsuke Sugawara
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasuaki Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yukiko Aihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shigenobu Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Juichiro Nakayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Shinichi Imafuku
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Naoya Yamazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenjiro Namikawa.

Ethics declarations

Conflict of interest

The authors have no conflict of interest to declare.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shibayama, Y., Namikawa, K., Sone, M. et al. Efficacy and toxicity of transarterial chemoembolization therapy using cisplatin and gelatin sponge in patients with liver metastases from uveal melanoma in an Asian population . Int J Clin Oncol 22, 577–584 (2017). https://doi.org/10.1007/s10147-017-1095-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-017-1095-0

Keywords

Search

Navigation